



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/596,200	06/02/2006	Rasoul Sedaghat Kerdar	512100-2058	3356

20999 7590 05/19/2010  
FROMMER LAWRENCE & HAUG  
745 FIFTH AVENUE- 10TH FL.  
NEW YORK, NY 10151

EXAMINER
----------

LEA, CHRISTOPHER RAYMOND

ART UNIT	PAPER NUMBER
----------	--------------

1619

MAIL DATE	DELIVERY MODE
-----------	---------------

05/19/2010

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/596,200	<b>Applicant(s)</b> KERDAR ET AL.	
	<b>Examiner</b> Christopher R. Lea	<b>Art Unit</b> 1619	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 29 March 2010.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 1-14 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-14 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 02 June 2006 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |                                                                                     |                                                                   |
|-------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                    | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)         | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____                                                         | 6) <input type="checkbox"/> Other: _____                          |

### **DETAILED ACTION**

This application is a 371 (national stage application) of PCT/EP04/14148.

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on March 29, 2010 has been entered.

Receipt of Amendments/Remarks filed on March 29, 2010, is acknowledged. In response to Final office action dated June 29, 2009, applicant amended claims 1 & 14 and added no new claims. Claims 1-14 are pending. Claims 1-14 are under examination.

Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. All new rejections applied have been necessitated by applicant's amendment to the claims. They constitute the complete set presently being applied to the instant application.

### ***Claim Rejections - 35 USC § 103***

1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the

Art Unit: 1619

invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

3. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

4. Claims 1-14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Rupprecht et al. (US PreGrant Publication 2002/0142036) in view of Levin (US Patent 6,432,986).

#### **Applicant claims**

Applicant claims a laminar film dosage form containing hydrophilic polymers and lidocaine.

**Determination of the scope and content of the prior art  
(MPEP 2141.01)**

Rupprecht et al. teach, as a whole, active agent-containing multi-layer film of hydrophilic polymers.

Claims 1, 2, 4, 6, 7, & 10-12: Rupprecht et al. teach an active agent-containing multi-layer film of film-forming polymers with a cover layer, at least one active substance-containing layer, and an adherent layer (paragraph 2). Rupprecht et al. teach that the adherent layer is mucoadhesive and the multi-layer film is useful for transmucosal, which includes nasal, administration (paragraphs 47 & 48 and claim 15). Rupprecht et al. teach that the active ingredient-containing layer consists of hydrophilic polymers crosslinked *in situ* (paragraph 8). Rupprecht et al. teach that lidocaine is among the possible active agents which may be incorporable into the multilayer film (paragraph 30). Rupprecht et al. teach the multi-layer film consists of up to 30% active substance based on the overall weight of the film (paragraph 46). This percentage overlaps with the claimed range of 30-60% when one considers that the claimed range is based only on the total weight of the crosslinked polymer, not the overall dosage form. Rupprecht et al. teach that the ratio of polymer to crosslinking agent is 4:1 to 1:1 (paragraph 12). Rupprecht et al. teach that the active substance in the active substance-containing layer may be distributed in horizontal or vertical gradients (paragraph 25). Determination of the starting and ending points of the gradient is a matter of optimizing the concentrations (results effective variables since Rupprechet et al. teach that gradient controls the release, paragraphs 24-26) through routine experimentation to generate a desired release profile (note that differences in

concentration are not generally supportive of patentability in the absence of evidence of unexpected results, MPEP §2144.05 II.A).

As to the claimed tear strength, where the claimed and prior art products are substantially identical in composition or produced by a substantially identical process, a *prima facie* case of either obviousness has been established. Further, The U.S. Patent Office is not equipped with analytical instruments to test prior art compositions for the infinite number of ways that a subsequent applicant may present previously unmeasured characteristics. When as here, the prior art appears to contain the exact same ingredients and applicant's own disclosure supports the suitability of the prior art composition as the inventive composition component, the burden is properly shifted to applicant to show otherwise. Absent evidence to the contrary, the prior art composition must possess the claimed tear strength, since it is substantially identical to the claimed composition (See *In re Best*, *In re Spada*, and MPEP § 2112.01 I).

Claims 3, 13, & 14: Rupprecht et al. teach cellulose ethers, particularly hydroxypropyl-methylcellulose as the hydrophilic polymers in the active substance-containing layer (paragraph 20).

Claim 5: Rupprecht et al. teach adding additional polymers to control the release of the active substance (paragraphs 23 & 24).

Claim 8: Rupprecht et al. teach that the active agent diffuses through the adherent layer, so the adherent layer is active ingredient containing. (paragraph 10). Further, Rupprecht et al. teach that (mucoadhesive) polyacrylic acid polymer (which makes the adherent layer adherent) may be added to the active substance-containing

Art Unit: 1619

layer, which would make allow an active substance-containing layer to be the adhesive layer (paragraph 23).

Claim 9: Rupprecht et al. teach that the covering layer acts as a barrier to prevent diffusion of (i.e., is impermeable to) the active agent (paragraph 10).

**Ascertainment of the difference between the prior art and the claims  
(MPEP 2141.02)**

The difference between the teachings of Rupprecht et al. and the instant claims is that Rupprecht et al. do not specifically embody the use of lidocaine as the active agent or teach the methods claimed. This deficiency in Rupprecht et al. is cured by the teachings of Levin.

Levin teaches, as a whole, compositions and methods for treating cerebral neurovascular disorders.

Levin teaches that intranasal administration of a composition comprising a sustained release formulation of a shorter-acting local anesthetic treats neurovascular headaches and other related disorders such as migraines (column 16, line 40-51 and column 17, lines 5-13). Levin exemplifies cocaine and lidocaine as shorter-acting local anesthetics (column 13, lines 53-59).

**Finding of *prima facie* obviousness  
Rationale and Motivation (MPEP 2142-2143)**

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the claimed invention was made to select lidocaine from the list of acceptable active agents and incorporate it into the dosage form taught by Rupprecht et al. and

Art Unit: 1619

produce the instant invention. The skilled artisan would have been motivated to do this because the selection of a known substance based on its suitability for its intended use would have been obvious to the skilled artisan. Further it would have been obvious to select lidocaine from the list based on its known abilities and functions as Levin teaches administering sustained-release lidocaine intranasally for the treatment of migraine headaches (column 18, lines 37-45); therefore, it would have been obvious to incorporate lidocaine into a dosage form that can be administered nasally, especially one that could offer control of the release profile, i.e. sustained release.

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in selecting lidocaine from the list of acceptable active agents and incorporating it into the dosage form taught by Rupprecht et al. and producing the claimed invention. Therefore, the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

In light of the forgoing discussion, one of ordinary skill in the art would have concluded that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103(a).

### ***Response to Arguments***

5. Applicant's arguments filed March 29, 2010, have been fully considered but they are not persuasive.



Applicant argues that the release and action of the lidocaine is "extended to at least five hours" which is a surprising and unexpected result. In order for the examiner to consider applicant's assertion of unexpected results, the applicant must compare the claimed invention with the closest prior art (in this case Rupprecht et al.). Applicant has not presented any experimental data showing that this (unclaimed) release profile is not obtainable from the prior art composition. Due to the absence of tests comparing applicant's dosage form with those of the closest prior art, we conclude that appellant's assertions of unexpected results constitute mere argument.

Ultimately, the examiner has determined that the claimed invention and the invention of Rupprecht et al. contain the same ingredients present in similar amounts, functioning in the same ways, and combined with similar methods. Levin et al. provides ample motivation for selecting and utilizing the lidocaine in the sustained-release dosage form taught by Rupprecht et al. As such, the skilled artisan would expect the prior art composition to possess the properties claimed. Therefore, the claimed invention is a combination of familiar elements according to known methods which is likely to be obvious when it does no more than yield predictable results.

The expected result remains the same; an intranasal dosage form is made in the absence of evidence to the contrary. No unexpected results have been presented. Applicant's arguments are not persuasive, and the rejection under 35 U.S.C. §103(a) is maintained.

***Conclusion***

Claims 1-14 are rejected. No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher R. Lea whose telephone number is (571) 270-5870. The examiner can normally be reached on Mon-Fri 8:00-4:00 ET.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne "Bonnie" Eyler can be reached on (571)272-0871. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/C. R. L./  
Examiner, Art Unit 1619

crl

/Ernst V Arnold/  
Primary Examiner, Art Unit 1616